DiagnosTear Ltd. – Approval to register first patent to its TeaRx™ technology

Tel Aviv (July 22, 2019) – BioLight is pleased to announce that its subsidiary, DiagnosTear Ltd. (“DiagnosTear“)[1], that is engaged in research, development and commercialization of a product that is based on DiagnosTear’s TeaRx™ technology, which is used to diagnose, personalize treatment and monitor dry eye syndrome by examining the composition of the tear film (“Diagnostear Product”  and the “TeaRx™ technology”),

announced today that it received its first approval to register a patent from the European Patent Office (the “Patent“).

[1] Holding via XL Vision Sciences Ltd. (wholly owned subsidiary) approx. 89% of the issued and share capital of Diagnostear (approx. 86% fully diluted).

Link to the complete article

Link to Newsroom

Comments are closed.